Roche Diabetes Care GmbH, Mannheim, Germany.
Steinbeis Innovationszentrum für Zellkulturtechnik, Mannheim, Germany.
J Diabetes Sci Technol. 2021 Jul;15(4):792-800. doi: 10.1177/1932296820908656. Epub 2020 Mar 1.
The increasing offering of patch-based medical devices is accompanied by growing numbers of reported adverse skin reactions. Procedures for testing leachables according to ISO 10993 may not be optimal for lipophilic substances that can be mobilized on skin by sweat and sebum. We propose an improved extraction method for targeted analysis of leachables using low volumes of a sweat-sebum emulsion. The approach is illustrated by the analysis of isobornylacrylate (IBOA), a compound found in some devices and suspected for allergenic potential.
Three patch-based products were tested: an implantable device for continuous glucose monitoring (CGM), an intermittently scanned CGM (isCGM) device, and a micro-insulin pump. Quantification of IBOA was performed by gas chromatography and allergenic potential of IBOA levels was assessed by the KeratinoSens cell assay. Different combinations were used for extraction solvent (isopropanol, 5% ethanol-water solution, and sweat-sebum emulsion), extraction volumes (complete immersion vs partial immersion in 2 mm of solvent), and extraction time (3, 5, and 14 days).
Isobornylacrylate was only found in the isCGM device. About 20 mg/L IBOA were eluted after 3 days in isopropanol but only about 1 mg/L in ethanol-water. Sweat-sebum emulsion dissolves IBOA better and gives a more stable solution than ethanol-water. Decomposition of IBOA solutions requires adjusted extraction timing or correction of results. In the sweat-sebum extract, IBOA levels were about 20 mg/L after 3 days and about 30 mg/L after 5 days, clearly above the threshold found in the KerationSens assay for keratinocyte activation (10 mg/L).
Extraction by low volumes of sweat-sebum emulsion can be a superior alternative for the targeted simulating-use assessment of leachables in patch-based medical devices.
随着贴剂式医疗器械的不断增加,报告的不良皮肤反应数量也在不断增加。根据 ISO 10993 进行浸出物测试的程序可能并不适用于亲脂性物质,这些物质可能会被汗液和皮脂从皮肤中动员出来。我们提出了一种使用低体积的汗液-皮脂乳液对贴剂式医疗器械中的浸出物进行靶向分析的改进提取方法。该方法通过对异冰片丙烯酸酯(IBOA)的分析得到了说明,IBOA 是一些器械中发现的一种化合物,有疑似致敏的潜在风险。
对三种贴剂式产品进行了测试:一种用于连续血糖监测(CGM)的植入式设备、一种间歇性扫描 CGM(isCGM)设备和一种微型胰岛素泵。通过气相色谱法对 IBOA 进行定量,并通过 KeratinoSens 细胞测定法评估 IBOA 水平的致敏潜力。提取溶剂(异丙醇、5%乙醇-水溶液和汗液-皮脂乳液)、提取体积(完全浸入与 2mm 溶剂部分浸入)和提取时间(3、5 和 14 天)采用了不同的组合。
IBOA 仅在 isCGM 设备中发现。在异丙醇中 3 天后洗脱约 20mg/L 的 IBOA,但在乙醇-水溶液中仅洗脱约 1mg/L。与乙醇-水溶液相比,汗液-皮脂乳液能更好地溶解 IBOA,并提供更稳定的溶液。IBOA 溶液的分解需要调整提取时间或对结果进行修正。在汗液-皮脂提取物中,3 天后 IBOA 水平约为 20mg/L,5 天后约为 30mg/L,明显高于 KerationSens 测定角化细胞激活的阈值(10mg/L)。
使用低体积的汗液-皮脂乳液提取可以作为替代方法,用于对贴剂式医疗器械中的浸出物进行模拟使用评估。